SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find out how well the drug Zolinza
(vorinostat) works in combination with the drug combination called CHOP (cyclophosphamide,
doxorubicin, vincristine, and prednisone) to treat patients with untreated T-cell
Non-Hodgkin's Lymphoma (NHL). The safety of these drugs in combination and the best dose of
vorinostat when given in combination with CHOP will also be studied.